---
document_datetime: 2024-03-14 08:45:02
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/sustiva-epar-procedural-steps-taken-authorisation_en.pdf
document_name: sustiva-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3697904
conversion_datetime: 2025-12-19 00:47:03.822597
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

<!-- image -->

1. Submission of the dossier The  applicant  DuPont  Pharmaceuticals  Limited  submitted  on  29  June  1998  an  application  for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Sustiva (efavirenz). After agreement by the CPMP on 28 January 1998, this medicinal product has been referred to Part B of the Annex of the Council Regulation  (EEC) 2309/93 of the 22 July 1993 as amended. The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Prof. R. Gaspar Co-Rapporteur: Dr. P. Sjöberg Licensing status: Sustiva  was  not  licensed  in  any  country  outside  or  inside  the  European  Union  at  the  time  of  the submission of the application. Sustiva has been licensed in the USA on 17 September 1998. 2. Steps taken for the assessment of the product · The procedure started on 24 July 1998. · The Rapporteur's assessment report was circulated to all CPMP members on 8 October 1998. The  Co-Rapporteur's  assessment  report  was  circulated  to  all  CPMP  members  on  2  October 1998. · The draft consolidated list of questions was circulated to all CPMP members on 11 November 1998 for discussion at the November plenary meeting. The CPMP adopted the consolidated list of questions on 19 November 1998. · The applicant submitted the responses to the CPMP consolidated list of questions to all CPMP members on 1 December 1998 and the evaluation restarted at the December CPMP meeting. · The joint Rapporteur/Co-Rapporteur assessment report on the responses to the consolidated list of questions was circulated to all CPMP members on 20 January 1999. · During the meeting in 23 - 24 February 1999, the CPMP agreed on a list of outstanding issues to be addressed by the applicant during an oral explanation which was held before the CPMP on 23 February 1999. In the light of the overall data submitted and the scientific discussion within the  Committee,  the  CPMP  issued  by  consensus  a  positive  opinion  for  granting  Marketing Authorisation for Sustiva 50, 100 and 200 mg hard capsules on 24 February 1999. · The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which issued the corresponding Decisions on 28 May 1999. Medicinal product no longer authorised

<!-- image -->

<!-- image -->